LY3200882 for Solid Cancers

Recruiting at 25 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Eli Lilly and Company

Disqualifiers: Cardiovascular disease, Systemic disorder, Leukemia

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-12 weeks

223 Participants Needed

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for people with solid tumors who can prove their cancer diagnosis, have good organ function, and are in decent physical shape (ECOG status of 0 or 1). They must be able to take pills. It's not for those with serious heart disease, other severe illnesses, or acute leukemia.

Inclusion Criteria

My organs are functioning well.

My cancer diagnosis was confirmed through lab tests on tissue or fluid samples.

I can swallow pills.

Exclusion Criteria

I do not have serious heart problems.

I do not have acute leukemia.

I do not have a serious illness besides my current condition.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3200882 in combination with other treatments such as Cisplatin, Radiation, or other drugs to evaluate safety

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• LY3200882

Trial Overview The study is testing the safety of a new drug called LY3200882 on solid tumors. Participants will also receive established cancer treatments like nab-Paclitaxel, radiotherapy, Cisplatin, LY3300054, and Gemcitabine.

Participant Groups

Group I: LY3200882 Schedule 2 Expansion Experimental Treatment 1 Intervention

Group II: LY3200882 Schedule 2 Escalation Experimental Treatment 1 Intervention

Group III: LY3200882 Schedule 1 Expansion Experimental Treatment 1 Intervention

Group IV: LY3200882 Schedule 1 Escalation Experimental Treatment 1 Intervention

Group V: LY3200882 + LY3300054 Experimental Treatment 2 Interventions

Group VI: LY3200882 + Gemcitabine + nab-Paclitaxel Experimental Treatment 3 Interventions

Group VII: LY3200882 + Cisplatin + Radiation Experimental Treatment 3 Interventions

Group VIII: Japanese Arm LY3200882 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University